来凯医药-B：LAE103的新药临床试验已获得美国食品药品监督管理局批准

Core Viewpoint - The company has received FDA approval for LAE103's IND, aiming to provide innovative treatments for patients with metabolic diseases requiring new therapeutic options [1] Group 1 - LAE103 is a selective antibody targeting ActRIIB [1] - The company is actively advancing this candidate drug into clinical research [1] - The goal is to offer innovative therapies for sarcopenic obesity and other muscle-related diseases [1]